These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 22426408)

  • 21. Improved survival trends in platinum-resistant patients with advanced ovarian, fallopian or peritoneal cancer treated with first-line paclitaxel/platinum chemotherapy: the impact of novel agents.
    Bamias A; Bamia C; Zagouri F; Kostouros E; Kakoyianni K; Rodolakis A; Vlahos G; Haidopoulos D; Thomakos N; Antsaklis A; Dimopoulos MA
    Oncology; 2013; 84(3):158-65. PubMed ID: 23296063
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Neoadjuvant chemotherapy followed by interval debulking surgery in patients with serous endometrial cancer with transperitoneal spread (stage IV): a new preferred treatment?
    Vandenput I; Van Calster B; Capoen A; Leunen K; Berteloot P; Neven P; Moerman P; Vergote I; Amant F
    Br J Cancer; 2009 Jul; 101(2):244-9. PubMed ID: 19568245
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Paclitaxel, epirubicin, and carboplatin in advanced or recurrent endometrial carcinoma: a Hellenic Co-operative Oncology Group (HeCOG) study.
    Papadimitriou CA; Bafaloukos D; Bozas G; Kalofonos H; Kosmidis P; Aravantinos G; Fountzilas G; Dimopoulos MA;
    Gynecol Oncol; 2008 Jul; 110(1):87-92. PubMed ID: 18455782
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Carboplatin and paclitaxel in advanced or metastatic endometrial cancer.
    Pectasides D; Xiros N; Papaxoinis G; Pectasides E; Sykiotis C; Koumarianou A; Psyrri A; Gaglia A; Kassanos D; Gouveris P; Panayiotidis J; Fountzilas G; Economopoulos T
    Gynecol Oncol; 2008 May; 109(2):250-4. PubMed ID: 18299146
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Continuous Low-Dose Oral Cyclophosphamide and Methotrexate as Maintenance Therapy in Patients With Advanced Ovarian Carcinoma After Complete Clinical Response to Platinum and Paclitaxel Chemotherapy.
    El-Husseiny K; Motawei H; Ali MS
    Int J Gynecol Cancer; 2016 Mar; 26(3):437-42. PubMed ID: 26825824
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Paclitaxel, Carboplatin, and Bevacizumab in Advanced and Recurrent Endometrial Carcinoma.
    Rose PG; Ali S; Moslemi-Kebria M; Simpkins F
    Int J Gynecol Cancer; 2017 Mar; 27(3):452-458. PubMed ID: 28187088
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A pilot study of paclitaxel and carboplatin for recurrent ovarian cancer.
    Adachi S; Ogasawara T; Ito K; Koyama M; Nagano T; Suzuki A; Yamada T; Nakata Y; Ozawa M
    Oncol Rep; 2001; 8(2):285-8. PubMed ID: 11182041
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The role of adjuvant chemotherapy in surgical stages I-II serous and clear cell carcinomas and carcinosarcoma of the endometrium: a collaborative study.
    Vandenput I; Trovik J; Vergote I; Moerman P; Leunen K; Berteloot P; Neven P; Salvesen H; Amant F
    Int J Gynecol Cancer; 2011 Feb; 21(2):332-6. PubMed ID: 21270614
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Intra-peritoneal cisplatin combined with intravenous paclitaxel in optimally debulked stage 3 ovarian cancer patients: an Izmir Oncology Group study.
    Unal OU; Yilmaz AU; Yavuzsen T; Akman T; Ellidokuz H
    Asian Pac J Cancer Prev; 2014; 15(15):6165-9. PubMed ID: 25124592
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A phase I trial combining carboplatin/doxorubicin with tocilizumab, an anti-IL-6R monoclonal antibody, and interferon-α2b in patients with recurrent epithelial ovarian cancer.
    Dijkgraaf EM; Santegoets SJ; Reyners AK; Goedemans R; Wouters MC; Kenter GG; van Erkel AR; van Poelgeest MI; Nijman HW; van der Hoeven JJ; Welters MJ; van der Burg SH; Kroep JR
    Ann Oncol; 2015 Oct; 26(10):2141-9. PubMed ID: 26216383
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Paclitaxel-carboplatin for advanced or recurrent carcinosarcoma of the uterus: the Japan Uterine Sarcoma Group and Tohoku Gynecologic Cancer Unit Study.
    Takano T; Otsuki T; Tokunaga H; Toyoshima M; Utsunomiya H; Nagase S; Niikura H; Ito K; Yaegashi N; Yamada H; Tase T; Kagabu M; Shoji T; Sugiyama T; Sato N; Fujimoto T; Terada Y; Nakahara K; Kurachi H; Yokoyama Y; Mizunuma H; Soeda S; Nishiyama H; Matsumoto T; Sato S; Shimada M; Kigawa J
    Int J Clin Oncol; 2014 Dec; 19(6):1052-8. PubMed ID: 24395448
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evaluation of paclitaxel/carboplatin in a dose dense or weekly regimen in 66 patients with recurrent or primary metastatic cervical cancer.
    Torfs S; Cadron I; Amant F; Leunen K; Berteloot P; Vergote I
    Eur J Cancer; 2012 Jun; 48(9):1332-40. PubMed ID: 22317951
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy and safety of the combination paclitaxel/carboplatin in patients with previously treated advanced ovarian carcinoma: a multicenter French Groupe des Investigateurs Nationaux pour l'Etude des Cancers Ovariens phase II study.
    Pujade-Lauraine E; Guastalla JP; Weber B; Curé H; Orfeuvre H; Mousseau M; Vincent P; Diéras V; Tubiana-Mathieu N; Jacquin JP; Mignot L; Leduc B; Paraïso D; Viens P
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-30-S15-35. PubMed ID: 9346219
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Gemcitabine for advanced endometrial cancer: a retrospective study of the Memorial sloan-Kettering Cancer Center experience.
    Grisham RN; Adaniel C; Hyman DM; Ma W; Iasonos A; Aghajanian C; Konner J
    Int J Gynecol Cancer; 2012 Jun; 22(5):807-11. PubMed ID: 22635030
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Feasibility Study of Adjuvant Chemotherapy Using Taxane Plus Carboplatin for High-Risk Patients With Uterine Cervical Non-Squamous Cell Carcinoma After Radical Hysterectomy.
    Sato S; Shimada M; Ohta T; Kojimahara T; Tokunaga H; Takano T; Yamaguchi S; Tanabe H; Nishio S; Kigawa J
    Int J Gynecol Cancer; 2016 Mar; 26(3):561-7. PubMed ID: 26825829
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Paclitaxel by 24- or 1-hour infusion n combination with carboplatin in advanced non-small cell lung cancer: the Fox Chase Cancer Center experience.
    Langer CJ; Leighton JC; Comis RL; O'Dwyer PJ; McAleer CA; Bonjo CA; Engstrom PF; Litwin S; Johnson S; Ozols RF
    Semin Oncol; 1995 Aug; 22(4 Suppl 9):18-29. PubMed ID: 7544025
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Carboplatin plus paclitaxel in the treatment of advanced or recurrent endometrial carcinoma.
    Michener CM; Peterson G; Kulp B; Webster KD; Markman M
    J Cancer Res Clin Oncol; 2005 Sep; 131(9):581-4. PubMed ID: 15959825
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A phase II trial of paclitaxel and carboplatin in women with advanced or recurrent uterine carcinosarcoma.
    Lacour RA; Euscher E; Atkinson EN; Sun CC; Ramirez PT; Coleman RL; Brown J; Gano JB; Burke TW; Ramondetta LM
    Int J Gynecol Cancer; 2011 Apr; 21(3):517-22. PubMed ID: 21436700
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Weekly paclitaxel and carboplatin combination chemotherapy in patients with advanced squamous cell carcinoma of the head and neck.
    Moosmann P; Egli F; Stahel RA; Jost L
    Onkologie; 2003 Dec; 26(6):568-72. PubMed ID: 14709932
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Iniparib plus paclitaxel and carboplatin as initial treatment of advanced or recurrent uterine carcinosarcoma: a Gynecologic Oncology Group Study.
    Aghajanian C; Sill MW; Secord AA; Powell MA; Steinhoff M
    Gynecol Oncol; 2012 Sep; 126(3):424-7. PubMed ID: 22634397
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.